Clinical Research Directory

Inclusion Criteria: * Patients with the diagnosis of neuroblastoma as defined by histopathology (confirmed by the PMC Department of Pathology), who will be operated for NB as standard of care procedure * Patients older than 1 year of age and not older than 18 years. * Written informed consent from patients and/or from parents or legal guardians, according to local law and regulations Exclusion Criteria: * Previous treatment with Dinutuximab-beta, either alone or in combination with chemotherapy * Pregnancy or positive pregnancy test (urine or serum) in females of childbearing potential. Pregnancy test must be performed within during the screening period and before the administration of the IMP. * Breast feeding. * Sexually active participants not willing to use highly effective contraceptive method (pearl index \<1) as defined in CTFG HMA 2020 (Appendix I) during trial participation and until 6 months after end of protocol therapy. * Patients that received prior treatment with chimeric antibodies.